• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Delcath Systems Inc.

Delcath prices $1.3m offering

September 30, 2016 By Fink Densford

Delcath (NSDQ:DCTH) today priced a $1.28 million public offering of stock, with funding slated to support clinical trials and commercialization efforts. The New York-based company said it plans to float 425,000 shares of its common stock at $3 per share. Investors in the round will also receive 0.35 warrants to purchase an additional share of common stock […]

Filed Under: Business/Financial News Tagged With: Delcath Systems Inc.

Delcath raises $35m in private placement

June 7, 2016 By Fink Densford

Delcath (NSDQ:DCTH) said today it inked a securities purchase agreement with an investor for $35 million in senior convertible notes and stock purchase warrants, expecting to bring in $32.2 million to support operations and ongoing clinical trials. Of the $32.2 million in proceeds, Delcath said $3 million will be immediately available, with the remaining $29.2 million […]

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: Delcath Systems Inc.

Delcath launches Phase III trial for ocular melanoma treatment

January 20, 2016 By Fink Densford

Delcath (NSDQ:DCTH) said today it launched a Phase III trial of its Delcath Hepatic Delivery System and Melphalan Hydrochloride designed for the treatment of hepatic dominant ocular melanoma. The newly initiated Focus trial will examine the safety, efficacy and pharmocokinetic profile of its Melphalan and HDS system when compared with the standard of care, the New […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Optical/Ophthalmic Tagged With: Delcath Systems Inc.

Delcath inks FDA deal for design of Phase III trial

January 20, 2016 By Fink Densford

Delcath (NSDQ:DCTH) said yesterday the company reached a special protocol assessment agreement with the FDA for the design of a Phase III trial of its Delcath Hepatic Delivery System and Melphalan Hydrochloride. The system is designed to treat patients with hepatic dominant ocular melanoma, the New York City-based company said. The company said the agreement acted as a […]

Filed Under: Clinical Trials, Drug-Device Combinations, Food & Drug Administration (FDA), Optical/Ophthalmic Tagged With: Delcath Systems Inc.

Siemens taps Abbott’s Pacitti for North American healthcare biz | Personnel Moves

October 7, 2015 By Brad Perriello

Siemens (NYSE:SI) said it lured Abbott (NYSE:ABT) executive David Pacitti to lead its North American Healthcare business, succeeding Dr. Gregory Sorensen. Siemens Healthcare made Pacitti, whose resume includes a 14-year spell at Guidant, president of Siemens Medical Solutions USA and head of its North America regional organization effective Oct. 19. “David Pacitti’s leadership experience at Abbott […]

Filed Under: Business/Financial News Tagged With: Abbott, BeneChill Inc., Boston Scientific, Delcath Systems Inc., dextera, Escalon Medical Corp., ICU Medical Inc., Personnel Moves, Philips, Pivot Medical, Siemens

Delcath wins FDA nod for Melphalan

July 20, 2015 By Fink Densford

Delcath (NSDQ:DCTH) said today it won Orphan Drug Designation from the FDA for melphalan, used in its hepatic delivery system to treat cholangiocarcinoma. Orphan drug designations are bestowed by the FDA on treatments for “orphan diseases”, usually defined as conditions that affect fewer than 200,000 people nationwide. The designation comes with benefits, such as tax credits, exclusivity […]

Filed Under: Drug Pumps, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Delcath Systems Inc., FDA

Delcath prices $7m follow-on offering

July 16, 2015 By Fink Densford

Delcath (NSDQ:DCTH) said today it priced a follow-on offering of 9.3 million units of stock it plans to float at 75¢ per share, slated to bring in $7 million for the company. Each unit in the offering consists of a share of common stock, 0.75 of a Series A warrant to purchase common stock at 87¢, a […]

Filed Under: Business/Financial News, Oncology Tagged With: Delcath Systems Inc.

Delcath to settle shareholder suits for $8.5m

July 8, 2015 By Fink Densford

Delcath (NSDQ:DCTH) said yesterday that it agreed to pay $8.5 million to settle a clutch of lawsuits filed by shareholders over losses related to its development of the drug-device combination Melblez kit. The lawsuits, filed by shareholders in 2013, sought compensation for losses between April 21, 2010, and May 2, 2013, stemming from 3 separate incidents the plaintiffs claim caused […]

Filed Under: Business/Financial News, Drug-Device Combinations, Legal News Tagged With: Delcath Systems Inc.

Delcath expands Phase II trial

December 19, 2014 By Val Kennedy Leave a Comment

Delcath expands Phase II trial

Delcath Systems (NSDQ:DCTH) said it added 2 German research centers to a global Phase II trial of its Chemosat melphalan hepatic delivery system in treating primary liver cancer.

Filed Under: News Well, Oncology Tagged With: Clinical Trials, Delcath Systems Inc.

Stryker hits a new lifetime high in shares | Medtech Wall Street news for the week of Apr. 7, 2014

April 10, 2014 By MassDevice Leave a Comment

Stryker shares hit new lifetime high | MassDevice.com On Call

April 7, 2014 by Arezu Sarvestani

MassDevice.com On Call

Filed Under: News Well, Wall Street Beat Tagged With: Cytomedix Inc., Deerfield Management, Delcath Systems Inc., NASDAQ, Stryker, TriVascular, Vital Therapies

Delcath Systems tanks following reverse stock split

April 9, 2014 By Arezu Sarvestani Leave a Comment

Delcath Systems tanks following news of reverse stock split

Shares of Delcath (NSDQ:DCTH) dropped more than 18% by the early afternoon today after the company proceeded with a 1-to-16 reverse stock split.

Filed Under: Drug-Device Combinations, News Well, Oncology, Wall Street Beat Tagged With: Delcath Systems Inc.

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Interim pages omitted …
  • Go to page 9
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS